AzTrials
AzTrials

Rheumatoid ArthritisPhase 2NCT00883896

Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis

A Phase 2 study testing ILV-094 in people with Rheumatoid Arthritis, run by Pfizer at 52 sites in 11 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of this study is to assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active rheumatoid arthritis who are taking methotrexate. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
ILV-094
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
195 participants
Where
52 sitesin 11 countries
Study dates
18 Jun 2009to 18 Feb 2011
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Meets the American College of Rheumatology (ACR) 1987 revised criteria for classification of Rheumatoid Arthritis (RA) for at least 6 months prior to screening
  • Active RA at the time of screening and baseline consisting of >= 5 swollen and >= 5 tender joints (28-joint count) and at least 1 of the following at screening: C-reactive protein >= 10 mg/L or Erythrocyte Sedimentation Rate >= 28 mm/h
  • Must be receiving methotrexate for at least 12 weeks, with a stable route and dose (up to 25 mg weekly) for at least 8 weeks prior to the baseline visit.

Who cannot join

  • Subjects with other rheumatic diseases
  • Cancer or history of cancer (other than cutaneous basal cell carcinoma and squamous cell carcinoma or in situ cervical cancer)
  • Any prior use of B cell-depleting therapy

Trial locations and contacts

52 sites in 11 countries.

52 sites in 11 countries

United States13 sites
  • Deaconess Hospital

    Cincinnati, Ohio, 45219

  • Arthritis Care and Diagnostic Center

    Dallas, Texas, 75231

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, 16635

  • Arizona Arthritis & Rheumatology Research, PLLC

    Glendale, Arizona, 85304

  • Diagnostic Rheumatology and Research PC

    Indianapolis, Indiana, 46227

  • Desert Medical Advances

    Palm Desert, California, 92260

  • Arthritis Center

    Palm Harbor, Florida, 34684

  • Arthritis & Osteoporosis Center of South Texas

    San Antonio, Texas, 78232

  • Clinical Research Advantage, Inc.

    Sarasota, Florida, 34233

  • The Arthritis Specialty Centre

    Sarasota, Florida, 34233

  • Clayton Medical Research

    St Louis, Missouri, 63117

  • Clinical Research Center of Reading

    West Reading, Pennsylvania, 19611

  • Clinical Research Center of Reading, LLC

    Wyomissing, Pennsylvania, 19610

Other trials in United States

Japan8 sites
  • Inoue Hospital

    Gunma, 370-0053

  • Matsubara Clinic

    Hyōgo, 650-0001

  • Matsubara Mayflower Hospital

    Hyōgo, 673-1462

  • Medical Corporation Wakoukai Kurashiki Kousai Hospital

    Kurashiki, Okayama-ken, 712-8044

  • Gunma University Hospital

    Maebashi, Gunma, 371-8511

  • National Hospital Organization Sagamihara National Hospital

    Sagamihara, Kanagawa, 228-8522

  • Institute of Rheumatology, Tokyo Women's Medical University Hospital

    Shinjyuku-ku, Tokyo, 162-0054

  • National Hospital Organization Shimoshizu National Hospital

    Yotsukaidou, Chiba, 284-0003

Other trials in Japan

Russia7 sites
  • Institute of Rheumatology of Russian academy of Medical Scie

    Moscow, 115522

  • City Clinical Hospital # 1 n.a. Pirogov

    Moscow, 119049

  • State Educational Institution of Additional Professional Education

    Saint Petersburg, 191015

  • State Health care institution of Leningrad Regional Clinical Hospital

    Saint Petersburg, 194291

  • State education institution of higher vocational education Smolensk State Medical Academy Roszdrav

    Smolensk, 214019

  • State Healthcare Institution Yaroslavl Regional Clinical Hospital

    Yaroslavl, 150062

  • Municipal Institution City Clinical Hospital #40

    Yekaterinburg, 620102

Other trials in Russia

Romania6 sites
  • SC Duo Medical SRL

    Bucharest, 010584

  • Spitalul Clinic Sf. Maria

    Bucharest, 011172

  • Spitalul Clinic Colentina

    Bucharest, 020125

  • Centrul de Boli Reumatismale Dr. I. Stoia

    Bucharest, 020983

  • Centrul Medical Terra Med

    Cluj-Napoca, Cluj, 400275

  • Spitalul Clinic Judetean de Urgenta Tg Mures

    Târgu Mureş, 540136

Other trials in Romania

Belgium5 sites
  • AZ Jan Palfijn

    Antwerp, 2170

  • Cliniques Universitaires St Luc Avenue Hippocrate 10 UCL

    Brussels, 1200

  • Universitair Ziekenhuis Gent

    Ghent, 9000

  • Reuma Instituut

    Hasselt, 3500

  • Chu Liege Sart Tilman B 35

    Liège, 4000

Other trials in Belgium

Colombia4 sites
  • Centro de Reumatologia y Ortopedia

    Barranquilla, Atlántico

  • Fundacion Instituto de Reumatologia Fernando Chalem

    Bogota, Cundinamarca

  • Medicity S.A.S

    Bucaramanga, Santander Department

  • Servimed EU

    Bucaramanga, Santander Department

Other trials in Colombia

Hungary4 sites
  • Budai Irgalmasrendi Hospital

    Budapest, 1023

  • Obudai Egeszsegugyi Centrum Kft

    Budapest, 1036

  • Josa Andras Oktatokorhaz Egeszsegugyi Szolgaltato Nonprofit Kft.

    Nyíregyháza, 4400

  • Markusovszky Hospital

    Szombathely, 9700

Other trials in Hungary

Croatia2 sites
  • University Hospital Centre Rijeka

    Rijeka, 51000

  • University Hospital Center Zagreb

    Zagreb, 10000

Other trials in Croatia

Germany1 site
  • Klinikum Innenstadt der Ludwig-Maximillians-Universität

    München, 80336

Other trials in Germany

Mexico1 site
  • Centro de Estudio de Investigacion Basica y Clinica S.C

    Jalisco, Guadalajara, 44690

Other trials in Mexico

Netherlands1 site
  • AMC

    Amsterdam, North Holland, 1105AZ

Other trials in Netherlands

About this study

Official title: RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ILV-094 ADMINISTERED SUBCUTANEOUSLY TO SUBJECT WITH RHEUMATOID ARTHRITIS.

The primary objective of this study is to assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active rheumatoid arthritis who are taking methotrexate.

Being tested
Placebo, ILV-094
Keywords
Rheumatoid Arthritis, ACR, Methotrexate, Interleukin-22
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboOther

    Part 1: Placebo SC administration every 2 weeks X 10 weeks.

  • ILV-094Drug

    Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.

  • ILV-094Drug

    Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.

  • PlaceboOther

    Part 2: Placebo SC administration every 2 weeks X 10 weeks

  • ILV-094Drug

    Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks

Study groups in NCT00883896
Study groupRoleWhat they receive
Arm 1Placebo comparatorPart 1: Placebo
Receives: Other: Placebo
Arm 2ExperimentalPart 1: 100 mg ILV-094 SC Q4W
Receives: Drug: ILV-094
Arm 3ExperimentalPart 1: 100 mg ILV-094 SC Q2W
Receives: Drug: ILV-094
Arm 4Placebo comparatorNot described
Receives: Other: Placebo
Arm 5ExperimentalPart 2: 200 mg ILV-094 SC Q2W
Receives: Drug: ILV-094

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With an American College of Rheumatology 20 Percent (ACR20) Response at Week 12

    ACR20 response: greater than or equal to (>=) 20 percent improvement in tender joint count; >=20 percent improvement in swollen joint count; and >=20 percent improvement in 3 of 5 remaining ACR core measures: participant's global assessment of disease activity (score: 0 [very well] to 10 [worst]); participant's assessment of pain (score: 0 [very well] to 100 [extremely bad]); physician global assessment of disease activity (score: 0 [very well] to 10 [worst]); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]) (score: 0 [no difficulty] to 3 [unable to do]); and C-reactive protein (CRP).

    Measured: Week 12

Secondary outcomes (15)
  1. Percentage of Participants With an American College of Rheumatology 20 Percent (ACR20) Response at Week 2, 4, 6, 8 and 10

    ACR20 response: >=20 percent improvement in tender joint count; >=20 percent improvement in swollen joint count; and >=20 percent improvement in 3 of 5 remaining ACR core measures: participant's global assessment of disease activity (score: 0 [very well] to 10 [worst]); participant's assessment of pain (score: 0 [very well] to 100 [extremely bad]); physician global assessment of disease activity (score: 0 [very well] to 10 [worst]); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]) (score: 0 [no difficulty] to 3 [unable to do]); and C-reactive protein (CRP).

    Measured: Week 2, 4, 6, 8, 10

  2. Percentage of Participants With an American College of Rheumatology 50 Percent (ACR50) Response at Week 2, 4, 6, 8, 10 and 12

    ACR50 response: >=50 percent improvement in tender joint count; >=50 percent improvement in swollen joint count; and 50 improvement in 3 of 5 remaining ACR core measures: participant's global assessment of disease activity (score: 0 [very well] to 10 [worst]); participant's assessment of pain (score: 0 [very well] to 100 [extremely bad]); physician global assessment of disease activity (score: 0 [very well] to 10 [worst]); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]) (score: 0 [no difficulty] to 3 [unable to do]); and C-reactive protein (CRP).

    Measured: Week 2, 4, 6, 8, 10, 12

  3. Percentage of Participants With an American College of Rheumatology 70 Percent (ACR70) Response at Week 2, 4, 6, 8, 10 and 12

    ACR70 response:>=70 percent improvement in tender joint count; >=70 percent improvement in swollen joint count; and 70 percent improvement in 3 of 5 remaining ACR core measures: participant's global assessment of disease activity (score: 0 [very well] to 10 [worst]); participant's assessment of pain (score: 0 [very well] to 100 [extremely bad]); physician global assessment of disease activity (score: 0 [very well] to 10 [worst]); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]) (score: 0 [no difficulty] to 3 [unable to do]); and C-reactive protein (CRP).

    Measured: Week 2, 4, 6, 8, 10, 12

  4. Disease Activity Score Based on 28-Joints Count (DAS28) Using C-Reactive Protein (CRP)

    DAS28 (CRP) was calculated from number of swollen joints and tender joints using the 28 joints count; CRP (milligram/Liter [mg/L]); and general health visual analog scale (VAS) score (participant rated scale with scores ranging from 0mm [very well] to 100mm [extremely bad]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 (CRP) less than or equal to (<=) 3.2 implied low disease activity, greater than (>) 3.2 to 5.1 implied moderate to high disease activity, and less than (<) 2.6 implied remission.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12

  5. Disease Activity Score Based on 28-Joints Count (DAS28) Using Erythrocyte Sedimentation Rate (ESR)

    DAS28 (ESR) was calculated from the number of swollen joints and tender joints using the 28 joints count; ESR (millimeters per hour [mm/hour]); and general health VAS score (participant rated scale with scores ranging from 0 [very well] to 100 [extremely bad]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 (ESR) <=3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity, and <2.6 implied remission.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12

  6. Tender Joints Counts (TJC)

    Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12

  7. Swollen Joints Count (SJC)

    Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12

  8. Physician Global Assessment of Disease Activity

    Physician global assessment of disease activity was measured on an 11-point scale, ranging from 0 to 10, where 0 = no disease activity and 10 = extreme disease activity.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12

  9. Participant Global Assessment of Disease Activity

    Participants answered: "considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a scale ranging from 0 to 10, where 0 = no disease activity and 10 = extreme disease activity.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12

  10. Pain Visual Analog Scale (VAS)

    Participants assessed the amount of pain currently experienced by them on a 100 millimeter (mm) VAS ranging from 0= no pain to 100= severe pain.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12

  11. General Health Visual Analog Scale (VAS)

    General health VAS is a 100 mm line marked by the participant. Participants were asked, "In general how would you rate your health currently concerning the arthritis?" Scores ranged from 0 mm = very well to 100 mm = extremely bad.

    Measured: Baseline, Week 2, 4, 6, 8, 10, 12

  12. Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

    Health assessment questionnaire-disability index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to perform activity. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Measured: Baseline, Week 4, 2, 6, 8, 10, 12

  13. 36-Item Short-Form Health Survey (SF-36)

    SF-36 is a standardized survey consisting of 36 items summarized into 8 multi-item scales evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality and mental health. Two summary scores, the physical component summary (PCS) and the mental component summary (MCS) derived are derived by aggregating the 8 aspects. The score for each aspect and physical and mental component summary are scaled 0-100 where, higher score indicating highest level of functioning.

    Measured: Baseline, Week 4, 8, 12

  14. Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale

    FACIT-fatigue is a 13-item questionnaire. Participants score each item on a 5-point scale ranging from 0 (not at all) to 4 (very much). The scoring algorithm is such that the item responses are reversed in score (except for 2 items, "I have energy" and "I am able to do my usual activities"), in order to reflect higher scores as less fatigue. The sum of all responses resulted in the FACIT-fatigue total score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.

    Measured: Baseline, Week 4, 8, 12

  15. Number of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28

    DAS28-based EULAR response criteria was used to measure individual response as none, good and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 =< 3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to =<5.1 or change from baseline >0.6 to =<1.2 with DAS28 =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28 >5.1.

    Measured: Week 2, 4, 6, 8, 10, 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Apr 2009 (estimated)
  2. Study start18 Jun 2009
  3. Primary completion18 Feb 2011
  4. Study completion18 Feb 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
195 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00883896
Sponsor's protocol ID
3199K1-2001
Other IDs
B1981001, 2008-006936-37, 2008
Status last verified
Sep 2022
First submitted
17 Apr 2009
Last updated
21 Oct 2022
Data monitoring committee
No
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing ILV-094 in people with Rheumatoid Arthritis, run by Pfizer at 52 sites in 11 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 52 sites in United States, Japan, Russia, Romania, Belgium and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 21 Oct 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With an American College of Rheumatology 20 Percent (ACR20) Response at Week 12 (time frame: Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in